Home > Boards > US OTC > Medical - Drugs > BioXcel Therapeutics Inc (BTAI)

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
crudeoil24 Member Profile
Member Level 
Followed By 678
Posts 45,514
Boards Moderated 11
Alias Born 12/12/04
160x600 placeholder
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 4/14/2021 5:17:16 PM
Universe Pharmaceuticals, Applied Molecular Transport leads healthcare gainers; AzurRx BioPharma, BioXcel Therapeutics among ... Seeking Alpha - 4/1/2021 11:04:34 AM
BioXcel Therapeutics shares fall after early-stage opioid withdrawal study results Seeking Alpha - 3/31/2021 4:40:00 PM
BioXcel Therapeutics Announces Results of Phase 1b/2 Study of BXCL501 for the Treatment of Opioid Withdrawal Symptoms GlobeNewswire Inc. - 3/31/2021 4:01:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/17/2021 5:01:23 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/15/2021 4:13:39 PM
BioXcel Therapeutics BXCL501 nabs accelerated review in U.S. for agitation in dementia Seeking Alpha - 3/15/2021 7:14:44 AM
BioXcel Therapeutics Receives FDA Breakthrough Therapy Designation for BXCL501 for the Acute Treatment of Agitation Associate... GlobeNewswire Inc. - 3/15/2021 7:00:00 AM
BioXcel Therapeutics seeks marketing approval for BXCL501 Seeking Alpha - 3/11/2021 10:26:13 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/11/2021 7:34:46 AM
BioXcel Therapeutics EPS beats by $0.07 Seeking Alpha - 3/11/2021 7:18:42 AM
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update GlobeNewswire Inc. - 3/11/2021 7:15:00 AM
BioXcel Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for BXCL501 for the Acute Treatment of... GlobeNewswire Inc. - 3/11/2021 7:00:00 AM
BioXcel Therapeutics to Host Fourth Quarter and Full Year 2020 Operating and Financial Results Conference Call and Webcast GlobeNewswire Inc. - 3/4/2021 7:00:00 AM
BioXcel's BXCL501 shows promising results in dementia related agitation Seeking Alpha - 3/3/2021 7:57:56 AM
BioXcel Therapeutics Provides Update on its BXCL501 Program for the Acute Treatment of Dementia Related Agitation GlobeNewswire Inc. - 3/3/2021 7:00:00 AM
BioXcel Therapeutics Appoints June Bray to Board of Directors GlobeNewswire Inc. - 3/1/2021 7:00:00 AM
BioXcel starts mid-stage BXCL501 trial for treatment of delirium related agitation Seeking Alpha - 2/25/2021 7:16:56 AM
BioXcel Therapeutics Announces Initiation of Phase 2 PLACIDITY Trial of BXCL501 for the Treatment of Delirium Related Agitati... GlobeNewswire Inc. - 2/25/2021 7:00:00 AM
BioXcel Therapeutics Appoints Javier Rodriguez as Chief Legal Officer and Corporate Secretary GlobeNewswire Inc. - 2/23/2021 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/18/2021 4:57:06 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/16/2021 5:40:15 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/16/2021 5:39:16 PM
Annual Statement of Changes in Beneficial Ownership (5) Edgar (US Regulatory) - 2/16/2021 5:35:27 PM
Annual Statement of Changes in Beneficial Ownership (5) Edgar (US Regulatory) - 2/16/2021 5:35:05 PM
crudeoil24 Member Level  Friday, 03/09/18 09:31:34 AM
Re: crudeoil24 post# 1
Post # of 28 
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer.

New York Yankees and Duke Basketball
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences